Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David L Porter

Showing results (21-30 of 199) with videos related to

Pageof 20
Sort By:
Expert Review of Hematology|November 19, 2010
Allogeneic immunotherapy to optimize the graft-versus-tumor effect: concepts and controversiesSteven C Goldstein, David L Porter
Oncology (Williston Park, N.Y.)|April 12, 2017
Commentary (Wakoff/Porter): The Biology and Treatment of Chronic Myelogenous LeukemiaAlison R Wakoff, David L Porter
Best Practice & Research. Clinical Haematology|September 26, 2006
Donor leukocyte infusions in myeloid malignancies: new strategiesDavid L Porter, Joseph H Antin
Oncology (Williston Park, N.Y.)|October 17, 2016
The Promise of Chimeric Antigen Receptor T-Cell TherapyNoelle V Frey, David L Porter
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|September 18, 2016
Chimeric Antigen Receptor T Cells and Hematopoietic Cell Transplantation: How Not to Put the CART Before the HorseSaad S Kenderian, David L Porter, Saar Gill
Gene|June 7, 2011
An inhibitor of eIF2 activity in the sRNA pool of eukaryotic cellsMichael Centrella, David L Porter, Thomas L McCarthy
Blood Reviews|November 18, 2015
Chimeric antigen receptor T cell therapy: 25years in the makingSaar Gill, Marcela V Maus, David L Porter
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 27, 2014
Novel treatments for chronic lymphocytic leukemia and moving forwardJennifer R Brown, David L Porter, Susan M O'Brien
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 2, 2019
Innovation and Access at the Mercy of Payment Policy: The Future of Chimeric Antigen Receptor TherapiesChristopher R Manz, David L Porter, Justin E Bekelman
British Journal of Haematology|December 16, 2016
The promise of chimeric antigen receptor T cells (CARTs) in leukaemiaRobert J Orlowski, David L Porter, Noelle V Frey
Pageof 20

Showing results (21-30 of 199) with videos related to

Sort By:
Pageof 20
Expert Review of Hematology|November 19, 2010
Allogeneic immunotherapy to optimize the graft-versus-tumor effect: concepts and controversiesSteven C Goldstein, David L Porter
Oncology (Williston Park, N.Y.)|April 12, 2017
Commentary (Wakoff/Porter): The Biology and Treatment of Chronic Myelogenous LeukemiaAlison R Wakoff, David L Porter
Best Practice & Research. Clinical Haematology|September 26, 2006
Donor leukocyte infusions in myeloid malignancies: new strategiesDavid L Porter, Joseph H Antin
Oncology (Williston Park, N.Y.)|October 17, 2016
The Promise of Chimeric Antigen Receptor T-Cell TherapyNoelle V Frey, David L Porter
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|September 18, 2016
Chimeric Antigen Receptor T Cells and Hematopoietic Cell Transplantation: How Not to Put the CART Before the HorseSaad S Kenderian, David L Porter, Saar Gill
Gene|June 7, 2011
An inhibitor of eIF2 activity in the sRNA pool of eukaryotic cellsMichael Centrella, David L Porter, Thomas L McCarthy
Blood Reviews|November 18, 2015
Chimeric antigen receptor T cell therapy: 25years in the makingSaar Gill, Marcela V Maus, David L Porter
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 27, 2014
Novel treatments for chronic lymphocytic leukemia and moving forwardJennifer R Brown, David L Porter, Susan M O'Brien
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 2, 2019
Innovation and Access at the Mercy of Payment Policy: The Future of Chimeric Antigen Receptor TherapiesChristopher R Manz, David L Porter, Justin E Bekelman
British Journal of Haematology|December 16, 2016
The promise of chimeric antigen receptor T cells (CARTs) in leukaemiaRobert J Orlowski, David L Porter, Noelle V Frey
Pageof 20